P : Caution when used during pregnancy
L : Caution when used during lactation
|| See TERMINOLOGY & ABBREVIATIONS ||
|Indication(s) & Dosage||Susceptible
Adult: As sulfate: 1-2 g every 12 hr via IV inj over 3-5 minutes or infuse over 20-30 minutes.
Renal impairment: Loading dose: 1-2 g followed by a maintenance dose adjusted according to CrCl.
|Special Precautions||Allergy to penicillin or to cephalosporins; renal impairment, monitor renal and haematological status; pregnancy and lactation.|
|Adverse Drug Reaction(s)||Rash, pruritus, urticaria; nausea,
vomiting, abdominal pain, diarrhoea; increased plasma levels of ASAT, ALAT, gamma-GT, LDH, bilirubin and/or alkaline phosphatase; interstitial nephritis,
acute renal failure; thrombocytopaenia, eosinophilia, haemolytic anaemia, neutropaenia, agranulocytosis; thrombophloebitis, pain at Inj site; convulsions,
Potentially Fatal: Pseudomembranous colitis.
|Drug Interactions||Reduced clearance with probenecid. Please consult detailed drug interactions before prescribing.|
|Lab Interference||Interferes with Jaffe method of creatinine conc measurement in determining renal function.|
|Storage||Intravenous: Store below 25Â°C.|
|Pharmacology||Cefpirome binds to one or
more of the penicillin-binding proteins (PBPs) which inhibits the final transpeptidation step of peptidoglycan synthesis in bacterial cell wall, thus
inhibiting biosynthesis and arresting cell wall assembly resulting in bacterial cell death.
Distribution: Widely distributed into body tissues and fluids; enters breast milk. Protein-binding: 10%
Excretion: Mainly by the kidneys via the urine (80-90% as unchanged); significantly removed by haemodialysis; 2 hrs (elimination half-life); prolonged in renal impairment.
|ATC Classification||J01DE02 - cefpirome.|